A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: DRUG: AZD9833|DRUG: Anastrozole|DRUG: Anastrozole placebo|DRUG: AZD9833 placebo|DRUG: Palbociclib|DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist
Sponsor: AstraZeneca